Emil Fraenkel, Ivica Lazúrová
Non- alcoholic steatohepatitis (NASH) belongs to the most prevalent liver diseases in the last years. Although more effective screening and diagnostic process participates in this fact, the higher prevalence is also caused by higher prevalence of obesity. Frequent association between steatosis (NASH), obesity, type II DM and impaired lipid metabolism led to assumption that insulin resistance could participate in the pathogenesis of the process. Insulin resistance is currently supposed to be the best reproducible predisposing factor of NASH and on the contrary - NASH is claimed to be one of the main forms of its manifestation. Exact localisation of impact places of pathogenic factors leading to hepatic insulin resistance as well as identification of the relationship between it and insulin resistance of other peripherical tissues could help it. The aim is an effective therapeutic influence of the process. The use of metformin seems to be the most promising therapeutical approach.